Hyperlipidaemia gene therapy - AmpliPhi Biosciences

Drug Profile

Hyperlipidaemia gene therapy - AmpliPhi Biosciences

Alternative Names: AAV-VLDLR

Latest Information Update: 04 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Targeted Genetics Corporation
  • Developer AmpliPhi Biosciences Corporation; Targeted Genetics Corporation
  • Class Antihyperlipidaemics; Gene therapies
  • Mechanism of Action LDL receptor agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • Available For Licensing Yes - Hyperlipidaemia

Highest Development Phases

  • No development reported Hyperlipidaemia
  • Discontinued Hyperlipoproteinaemia type II

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for preclinical development in Hyperlipidaemia in USA
  • 09 Mar 2011 Targeted Genetics Corporation is now called AmpliPhi Biosciences
  • 11 Nov 2010 This programme is in active development
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top